Anti-myelin oligodendrocyte glycoprotein antibody in demyelinating diseases

Ichiro Nakashima

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)


Anti-myelin oligodendrocyte glycoprotein (MOG) antibody, which is specifically detected using a cell-based assay (CBA), has been identified in various demyelinating diseases, including neuromyelitis optica spectrum disorders (NMOSD), acute idiopathic optic neuritis (ON), and pediatric multiphasic disseminated encephalomyelitis. Although its pathogenic role has not been established, antibody seropositive cases appear to share several characteristic features, such as a preferable response to steroid therapy and a good prognosis. Antibody detection at the onset of a demyelinating disease is important to predict the prognosis. Further analysis of the clinical features and investigation of the pathogenic roles of the antibody are required to establish the disease spectrum associated with the antibody. Although the associated diseases appear to have a relatively good prognosis, treatment recommendations are offered for patients with severe symptoms or frequent relapses.

Original languageEnglish
Pages (from-to)59-63
Number of pages5
JournalClinical and Experimental Neuroimmunology
Publication statusPublished - 2015 Dec 1


  • acute disseminated encephalomyelitis
  • multiple sclerosis
  • myelin oligodendrocyte glycoprotein
  • neuromyelitis optica spectrum disorders
  • optic neuritis

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology
  • Immunology and Microbiology (miscellaneous)
  • Clinical Neurology


Dive into the research topics of 'Anti-myelin oligodendrocyte glycoprotein antibody in demyelinating diseases'. Together they form a unique fingerprint.

Cite this